Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions.

Khalilieh SG, Yee KL, Sanchez RI, Fan L, Anderson MS, Sura M, Laethem T, Rasmussen S, van Bortel L, van Lancker G, Iwamoto M.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e02016-18. doi: 10.1128/AAC.02016-18. Print 2019 May.

2.

Switchability of Gabapentin Formulations: A Randomized Trial to Assess Bioequivalence Between Neurontin and Gabasandoz on the Individual Subject Level.

Van Lancker G, Van Bortel L, Delafontaine B, Boussery K, Swart E, Chahbouni A, Van Bocxlaer J, Colin P.

Clin Pharmacol Ther. 2019 Jul;106(1):195-203. doi: 10.1002/cpt.1353. Epub 2019 Mar 2.

PMID:
30636281
3.

KH176 under development for rare mitochondrial disease: a first in man randomized controlled clinical trial in healthy male volunteers.

Koene S, Spaans E, Van Bortel L, Van Lancker G, Delafontaine B, Badilini F, Beyrath J, Smeitink J.

Orphanet J Rare Dis. 2017 Oct 16;12(1):163. doi: 10.1186/s13023-017-0715-0.

Supplemental Content

Loading ...
Support Center